A growing entrepreneurial culture among medical innovators at the University of Southampton was praised by senior industry leaders at the official launch of the Future Worlds medicine initiative in London.
The Chancellor today delivered his first Budget of the current government by saying that “the UK is on the brink of a technological revolution” and promising to “invest to secure a bright future”. Among the announcements is the outcome of the Patient Capital Review, which will deliver a £20bn package over the next 10 years to support investment in innovative UK companies.
The Chancellor has today announced the outcome of the Patient Capital Review, which will deliver a £20bn package to support investment in innovative companies over the next 10 years. The Review was launched by chancellor Phillip Hammond a year ago and has been looking at how to increase access to finance, and especially long-term investment, for innovative growing companies. The outcome of the review has been hotly anticipated by the bioscience sector and key policies announced today were called for in the recent BIA response to the Patient Capital Review.
This is a big week for the sector and we expect the new location of the EMA to be announced later on today. We will keep members updated on all the news in our next Brexit webinar tomorrow. Losing the EMA is a bitter pill to swallow for the UK but it’s vital that the agency can continue to function wherever it is moved to. The focus must be on ensuring that there is a smooth transition to allow for this to happen so that we do not see a detrimental impact on the supply of medicines to patients in the UK and EU.
Genomics is about making sense of genetic information and using that to learn about human biology to improve the way we develop drugs and healthcare.
Genomics plc was founded three years ago by four academics from the University of Oxford and wanted to help transform healthcare and they've now grown to over 30 people.
One of the many highlights of this year’s UK Bioscience Forum, held on October 12th, was Sir John Bell’s keynote speech. To an audience of 300 delegates from the world of UK bioscience, he gave what felt like a State of the Union address for the sector, extolling our strengths and recognising where there are challenges. Having only recently written and launched his highly anticipated Life Sciences Industrial Strategy, Sir John had a wealth of relevant advice and insight to share with the bioscience community, so what were the key take-home messages from the speech?
The annual international 3Rs award, sponsored by the NC3Rs and GlaxoSmithKline, recognises primary research which has made a significant contribution to advancing the 3Rs in medical, biological or veterinary sciences.